The FDA criticized Eli Lilly for three manufacturing-related shortcomings in Form 483 filings released the week of May 4. The FDA reprimanded the company following an inspection of the pharmaceutical giant in the fall of 2022, which revealed its filling line operations were “deficient.”
Read the full post on Becker's Hospital Review - Healthcare News
